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Abstract
ICON: Anaphylaxis provides a unique perspective on the principal evidence-based anaphylaxis guidelines
developed and published independently from 2010 through 2014 by four allergy/immunology organizations.
These guidelines concur with regard to the clinical features that indicate a likely diagnosis of anaphylaxis – a
life-threatening generalized or systemic allergic or hypersensitivity reaction.
They also concur about prompt initial treatment with intramuscular injection of epinephrine (adrenaline) in
the mid-outer thigh, positioning the patient supine (semi-reclining if dyspneic or vomiting), calling for help,
and when indicated, providing supplemental oxygen, intravenous fluid resuscitation and cardiopulmonary
resuscitation, along with concomitant monitoring of vital signs and oxygenation. Additionally, they concur
that H1-antihistamines, H2-antihistamines, and glucocorticoids are not initial medications of choice.
For self-management of patients at risk of anaphylaxis in community settings, they recommend carrying
epinephrine auto-injectors and personalized emergency action plans, as well as follow-up with a physician
(ideally an allergy/immunology specialist) to help prevent anaphylaxis recurrences.
ICON: Anaphylaxis describes unmet needs in anaphylaxis, noting that although epinephrine in 1 mg/mL
ampules is available worldwide, other essentials, including supplemental oxygen, intravenous fluid
resuscitation, and epinephrine auto-injectors are not universally available.
ICON: Anaphylaxis proposes a comprehensive international research agenda that calls for additional
prospective studies of anaphylaxis epidemiology, patient risk factors and co-factors, triggers, clinical criteria for
diagnosis, randomized controlled trials of therapeutic interventions, and measures to prevent anaphylaxis
recurrences. It also calls for facilitation of global collaborations in anaphylaxis research.
In addition to confirming the alignment of major anaphylaxis guidelines, ICON: Anaphylaxis adds value by
including summary tables and citing 130 key references. It is published as an information resource about
anaphylaxis for worldwide use by healthcare professionals, academics, policy-makers, patients, caregivers, and
the public.
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Introduction
The prevalence of allergic diseases is increasing
worldwide, attributed in part to increased exposure to
environmental allergens and pollutants; nevertheless,
these diseases remain under-diagnosed and under-
treated. Within the framework of the International
Collaboration in Asthma, Allergy, and Immunology
(iCAALL), the World Allergy Organization (WAO)
and three member organizations of the WAO feder-
ation of allergy organizations (the American Academy
of Allergy, Asthma and Immunology [AAAAI], the
American College of Allergy, Asthma and Immun-
ology [ACAAI], and the European Academy of Al-
lergy and Clinical Immunology [EAACI]) have united
to increase global awareness of allergic diseases and
to promote their evidence-based management. In this
collaborative outreach program, international consen-
sus (ICON) documents are being published as re-
sources to provide information about allergic diseases
for physicians, other healthcare professionals, policy-
makers, patients, caregivers, and the public [1].
This ICON: Anaphylaxis paper focuses on the prin-
cipal anaphylaxis guidelines developed and published
independently by the collaborating organizations
from 2010 through 2014 [2-4], other anaphylaxis-
relevant guidelines and publications from these orga-
nizations [5-22], and more than 100 additional key
publications [23-124] that contribute to the evidence
base for diagnosis, management, and prevention of
anaphylaxis. In addition, it describes unmet global
needs in the diagnosis and treatment of anaphylaxis
in high-, mid-, and low-resource countries [125-130]
and proposes an international agenda for anaphylaxis
research.
Methods
The ICON: Anaphylaxis author group was identified
by the 2012-2013 WAO Board of Directors based on
global representation and comprised mainly of
allergy/immunology specialists who had contributed
to previous national and international anaphylaxis
publications.
The WAO Anaphylaxis Guidelines [2], the AAAAI/
ACAAI Anaphylaxis Guidelines (Practice Parameters)
[3] and the EAACI Anaphylaxis Guidelines [4] were cir-
culated to all co-authors, who reviewed them, responded
to four sequential calls for input about them sent by
e-mail during 2013, and supplied additional relevant
references. Each call for input consisted of a series of
detailed questions about anaphylaxis that focused on
definition, diagnosis, treatment in healthcare settings,
and post-discharge management including prevention
of recurrences. Co-authors were asked to review the col-
laborating organizations’ principal guidelines and identify
areas where they concurred, areas where emphasis
differed, and areas where little or no information was
provided. They were also asked to provide their per-
spectives on unmet needs in anaphylaxis and propose
topics for an international anaphylaxis research
agenda. The co-author response rate was 100% to all
but one call for input (86%).
The lead author collated the responses. Areas
where the co-authors failed to agree were discussed
by e-mail correspondence. The lead author then
drafted the ICON: Anaphylaxis manuscript, which
was developed further by internal reviews by the co-
authors (with 100% participation) and revisions. This
was followed by external review by the iCAALL
Steering Group, final revisions, and submission for
publication. The co-authors met in person to discuss
the ICON: Anaphylaxis document on June 25, 2013
during the World Allergy & Asthma Congress in
Milan.
Overview of collaborating organizations’ principal
anaphylaxis guidelines
An overview of the unique aspects of the principal
anaphylaxis guidelines published by collaborating
organizations is provided in Table 1 [2-4]. Although
they vary in some areas of emphasis and in style,
length, and referencing, their recommendations
on anaphylaxis are aligned with regard to clinical
diagnosis, initial treatment, and prevention of
recurrences.
The widely disseminated WAO Anaphylaxis Guide-
lines [2], developed by the WAO Special Committee
on Anaphylaxis, are supported by global assessments
of essentials for anaphylaxis diagnosis and treatment
[5-7] and yearly updates [8,9] of the evidence sup-
porting the recommendations made in the guidelines.
They provide a comprehensive, practical view of ana-
phylaxis. The text is closely linked with detailed illus-
trations that focus on patient risk factors, co-factors
that amplify anaphylaxis, mechanisms, triggers, prin-
ciples of clinical diagnosis, treatment, and post-
discharge management. The illustrations on clinical
diagnosis and prompt initial treatment have been
translated into numerous languages and globally dis-
tributed as posters, pocket cards, and patient informa-
tion cards.
The AAAAI/ACAAI Anaphylaxis Guidelines (Prac-
tice Parameters) [3] were developed by the Joint Task
Force on Practice Parameters (representing the
AAAAI, the ACAAI, and the Joint Council of Allergy
Asthma and Immunology), which has a long history
of publishing practice parameters on anaphylaxis
[10-12] and related subjects [13-16]. These guidelines
feature detailed descriptions of many anaphylaxis
Simons et al. World Allergy Organization Journal 2014, 7:9 Page 2 of 19
http://www.waojournal.org/content/7/1/9
triggers and of idiopathic anaphylaxis. They describe
clinical and laboratory diagnosis, initial treatment of
anaphylaxis, treatment of refractory anaphylaxis, and
post-discharge management. Many allergy/immunology spe-
cialists self-report adherence to these guidelines [17].
The EAACI 2014 Guidelines [4] were developed ac-
cording to the Institute of Medicine Guidelines for
Clinical Practice [18]. Co-authors included: allergy/
immunology specialists, emergency medicine special-
ists, population health scientists, primary care physi-
cians, and representatives from patient organizations.
These guidelines are supported by previous guide-
lines [19] and relevant concurrent publications that
include systematic reviews of the epidemiology of
anaphylaxis [20] and management of anaphylaxis
[21], and the EAACI Food Allergy Guidelines [22].
They emphasize the role of anaphylaxis education in
long-term management and provide practical recom-
mendations for training physicians, other healthcare
professionals, patients, and caregivers [4].
Comparative review of collaborating
organizations’ principal anaphylaxis guidelines
Scrutiny of collaborating organizations’ guidelines reveals
many areas of consensus, some areas where emphasis
differs, and a few areas where minimal information is
provided [2-4] (Table 2, 3, 4, and 5). Additional key
publications representing global anaphylaxis research rele-
vant to each area are cited as resources [5-124].
Definition of anaphylaxis
In these guidelines, the independently developed defini-
tions of anaphylaxis for clinical use by healthcare profes-
sionals all include the concepts of a serious, generalized
or systemic, allergic or hypersensitivity reaction that can
be life-threatening or fatal. Importantly, none of the defi-
nitions include the word “shock” [2-4] (Table 2). The
correct term “anaphylaxis” is preferred to “anaphylactic
shock” because shock is not necessarily present in pa-
tients with anaphylaxis [23-26]. The term “anaphylaxis”
should also be used in preference to terms such as “aller-
gic reaction”, “acute allergic reaction”, “systemic allergic
reaction”, “acute IgE-mediated reaction”, “anaphylactoid
reaction”, or “pseudo-anaphylaxis” [2-4].
Epidemiology
None of the guidelines has a major focus in this area
[2-4]; however, they all include important information
about anaphylaxis epidemiology supported by relevant
references [2-4,27-37] (Table 2).
Patient-specific risk factors and co-factors relevant to
anaphylaxis
The guidelines concur about the importance of patient-
specific risk factors and co-factors in anaphylaxis [2-4].
Table 1 Overview of collaborating organizations’ principal anaphylaxis guidelines1
WAO Guidelines AAAAI/ACAAI2 Guidelines EAACI Guidelines
Year of publication 2011 2010 2014
Authors Simons FER et al (10 co-authors) Lieberman P et al (15 contributors) Muraro A et al (28 co-authors)
Countries represented
by authors
Argentina, Canada, Egypt, Germany,
Italy, Singapore United Kingdom,
United States, Venezuela
United States Canada, Denmark, France,
Germany, Italy, Ireland, The
Netherlands, Poland, Portugal,
Spain, Switzerland, United Kingdom
Methods consensus consensus consensus using AGREE II
methodology
Length (number of
journal pages)
7 page summary, 22 e-pages 4 page summary, 30 e-pages 20 pages
References total: 150; 80% published 2006-13 total: 311; 13% published 2006-13 total: 133; 68% published 2006-13
Tables, Figures, Boxes,
Appendices
9 tables; 5 figures (illustrations) 8 e-tables; 4 e-figures (algorithms) 2 figures (algorithms); 15 boxes;
4 online supplements
Dissemination and uptake key figures on diagnosis and treatment
translated3 and widely disseminated
as posters, pocket cards and patient
information cards
utilized by allergy/immunology
specialists
published in 2014
Unique aspects developed and funded by WAO;
evidence-based; global perspective;
key points highlighted using color
illustrations; allergists’ role highlighted;
anaphylaxis in limited-resource areas
discussed; research agenda
developed and funded by AAAAI/
ACAAI/Joint Council2; evidence-based;
detailed information on triggers;
specific information on refractory
anaphylaxis; allergists’ role highlighted
developed and funded by EAACI;
evidence-based; participants from
many disciplines; allergists’ role
highlighted; emphasis on practical
aspects of long-term management;
research agenda
1See text pages 2-3 for details, 2developed by the Joint Task Force on Practice Parameters, the AAAAI, the ACAAI, and the Joint Council of Allergy Asthma and
Immunology, 3available in Arabic, English, French, German, Italian, Japanese, Korean (2014), Mandarin (2014), Polish, Portuguese, Russian, Spanish, and Turkish.
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The WAO Guidelines emphasize risk factors related to
age (infancy, adolescence, advanced age), physiologic
state (pregnancy), concomitant diseases including asthma,
cardiovascular diseases (CVD), and mastocytosis, and
concurrent medications such as beta-blockers and angiotensin-
converting enzyme (ACE) inhibitors. The AAAAI/ACAAI
Guidelines describe patient-specific risk factors such as
asthma, CVD, and mastocytosis, and concurrent beta-
blocker and ACE-inhibitor use. The EAACI Guidelines in-
clude a major focus on asthma as a patient risk factor
(Table 2).
The guidelines also concur about the relevance of
co-factors that amplify [2-4] anaphylaxis. The WAO
Guidelines and EAACI Guidelines provide an overview
of co-factors such as exercise, emotional stress, acute
infection, fever, concomitant ingestion of ethanol or a non-
steroidal anti-inflammatory drug (NSAID), disruption of
routine, and perimenstrual status. The AAAAI/ACAAI
Guidelines focus on exercise. The importance of risk factors
[38-49] and amplifying co-factors [33,50,51] that potentially
impact anaphylaxis is now widely acknowledged; indeed,
co-factors are now reported to be relevant in 20-30% of
anaphylactic episodes [33,50].
None of the guidelines describe the relationship be-
tween mast cell activation disorders (MCAD) and ana-
phylaxis, perhaps because the first international consensus
document on classification of MCAD was only published
in 2012 [45].
Underlying mechanisms
The WAO Guidelines provide a brief overview of IgE-
dependent and IgE-independent immunologic mecha-
nisms and direct mast cell stimulation in anaphylaxis
[2]. The AAAAI/ACAAI Guidelines describe immuno-
logic mechanisms and direct mast cell activation in the
context of different triggers [3]. The EAACI Guidelines
focus mainly on IgE-mediated anaphylaxis [4] (Table 2).
None of the guidelines provide optimal information on
IgG-mediated anaphylaxis in humans, an emerging area
of investigation [52].
Table 2 Essential information on anaphylaxis: summary of collaborating organizations’ principal anaphylaxis
guidelines1
WAO Guidelines AAAAI/ACAAI Guidelines EAACI Guidelines
Definition of anaphylaxis "a serious life-threatening
generalized or systemic
hypersensitivity reaction"
and “a serious allergic
reaction that is rapid in
onset and might cause death"
"an acute life-threatening
systemic reaction with varied
mechanisms, clinical presentations,
and severity that results from
the sudden release of mediators
from mast cells and basophils"
"a severe life-threatening
generalized or systemic
hypersensitivity reaction"
Epidemiology not a major emphasis not a major emphasis summary of anaphylaxis
epidemiology and clinical
presentation: gaps in the
evidence (Box 15)
Patient risk factors and
co-factors relevant to
anaphylaxis
describe vulnerability related
to age, concomitant diseases
(asthma, CVD, mastocytosis),
concurrent medications
(beta-blockers, ACE inhibitors);
describe co-factors such as
exercise, acute infection,
emotional stress, premenstrual
status, and ethanol or NSAID
ingestion; Figure 1
describe concomitant diseases
(asthma, CVD, mastocytosis),
concurrent medications
(beta-blockers, ACE inhibitors);
mention premenstrual status as
a co-factor
give examples of patient-
specific factors, pre-existing
conditions, medications and
lifestyle factors; describe
concomitant asthma in
detail; Box 6
Underlying mechanisms provide an overview of immunologic
mechanisms (IgE-dependent and
IgE-independent), non-immunologic
(direct mast cell activation) and
idiopathic anaphylaxis (no apparent
trigger); Figure 2
describe immunologic mechanisms
in the context of different
anaphylaxis triggers; describe
idiopathic anaphylaxis; Table E7
major focus on IgE-mediated
anaphylaxis to food, insect
venoms, and drugs; other
mechanisms are mentioned
Anaphylaxis triggers
(causes, elicitors, or
inducers)
describe most triggers; state that
the relative importance of specific
triggers varies in different age groups
and different global regions; Figure 2
describe many triggers in detail,
with major emphasis on foods,
venoms, drugs, biological agents,
perioperative agents, radiocontrast
media, latex, exercise, human
seminal fluid, and idiopathic
anaphylaxis; Table E5
overview of some triggers;
describe food triggers in
considerable detail; state that
the importance of triggers
varies with age and geography
1For details, see ICON: Anaphylaxis text pages 3-5 and references 2, 3 and 4, including the tables, figures, and boxes that are mentioned above in this Table.
ACE, angiotensin-converting enzyme; CVD, cardiovascular disease; NSAID, non-steroidal anti-inflammatory drug.
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Anaphylaxis triggers (Causes, Elicitors, or Inducers)
The WAO Guidelines describe triggers and idiopathic
anaphylaxis concisely, and note that different triggers
predominate in different age groups and different global
regions [2]. The AAAAI/ACAAI Guidelines provide de-
tailed information about many triggers including foods,
stinging insect venoms, drugs, biological agents, peri-
operative agents, radiocontrast media, latex, subcutane-
ous allergen immunotherapy, and human seminal fluid;
also about idiopathic anaphylaxis [3]. The EAACI
Guidelines emphasize food triggers, provide information
on stinging insect venom and drug triggers, and state
that the relative importance of triggers varies with age
and geography [4] (Table 2).
Anaphylaxis triggers such as food, venom, and drugs have
been studied in Australia, Europe, North America, and be-
yond; for example, in Asia (China, Japan, Korea, Singapore,
and Thailand), and South America (Argentina, Brazil,
and Venezuela) [27-37,53-66]. In any region, the relative
importance of triggers can change over time [54].
Clinical diagnosis of anaphylaxis
Collaborating organizations’ guidelines concur about
making the clinical diagnosis of anaphylaxis based on
recognition of sudden onset of characteristic symptoms
and signs within minutes to hours after exposure to a
known or likely trigger [2-4]. They all list the clinical cri-
teria for diagnosis of anaphylaxis that were developed as
an instrument for rapid assessment of patients who
present with a possible diagnosis of anaphylaxis [23] and
are validated for use in medical settings and in epidemi-
ologic studies [67,68] (Table 3).
The guidelines also concur that laboratory tests are not
helpful in diagnosing anaphylaxis at the time of patient
presentation [2-4]. Measurement of a biologic marker
such as serum total tryptase takes hours and test results
are not available on an emergency basis. Elevation in bio-
logic marker levels correlates with anaphylaxis severity
[24]; platelet-activating factor levels appear to correlate
better than tryptase or histamine levels do [69]. Tryptase
levels are elevated in only about 60% of adults with clinic-
ally confirmed anaphylaxis [70] and are seldom elevated in
children with anaphylaxis or in food-induced anaphylaxis.
The reference range for tryptase levels in infants has been
established [71]. Tryptase levels (or levels of any other bio-
logic markers) within the normal reference range do not
rule out anaphylaxis. Lack of availability of biologic
marker measurements is not a barrier to prompt clinical
diagnosis of anaphylaxis [2-4].
In addition to the above, all the guidelines provide a
perspective on the differential diagnosis of anaphylaxis
[2-4] (Table 3).
Prompt initial treatment of anaphylaxis
Importantly, collaborating organizations’ guidelines con-
cur with regard to recommendations for prompt initial
treatment of anaphylaxis with epinephrine (adrenaline)
injected intramuscularly in the mid-outer thigh, and re-
peating the epinephrine dose after 5-15 minutes if the re-
sponse to the first injection is not optimal [2-4] (Table 4).
The guidelines concur about the importance of pre-
paredness to diagnose and treat anaphylaxis and about
other measures such as rapid assessment of the patient,
removing the trigger if possible, and calling for help.
Table 3 Diagnosis of anaphylaxis: summary of collaborating organizations' principal anaphylaxis guidelines1
WAO Guidelines AAAAI/ACAAI Guidelines EAACI Guidelines
Symptoms and signs
(typically within minutes to
hours after exposure; multi-
system; rapid progression)
describe symptoms and signs in
detail; Table 2
describe symptoms and signs; list
frequency of symptoms and signs in
different organ systems; Table E1
describe symptoms and signs;
Figure 1
Clinical criteria for diagnosis
of anaphylaxis
primary emphasis on clinical diagnosis;
clinical criteria for diagnosis are listed
and illustrated; Table 1, Figure 3
primary emphasis on clinical
diagnosis: state “the history is the
most important tool”; clinical criteria
for diagnosis are listed; Figure E1
primary emphasis on clinical
diagnosis: clinical criteria for
diagnosis are listed; Box 4
Laboratory tests for
confirmation of the
clinical diagnosis
describe use of tryptase or histamine
measurements and other tests in a
supportive role; emphasize correct
timing of blood samples; Table 3
describe use of tryptase or histamine
measurements and other tests in a
supportive role; emphasize correct
timing of blood samples; Table E3
describe use of tryptase
measurements in a
supportive role
Differential diagnosis comprehensive list provided; additional
laboratory tests for ruling out other
diagnoses are described; Table 4
comprehensive list provided;
additional laboratory tests for ruling
out other diagnoses are described;
Tables E2, E3
comprehensive list provided,
including detailed list of
neuropsychiatric diseases; Box 5
Diagnosis of anaphylaxis in
special populations
include reference ranges for vital signs
in infants and children, and discuss
relevant clinical and lab issues in infants,
pregnant women and the elderly; Figure 1
include normal values for vital signs in
infants and children; Table E4
describe patient-specific
factors: examples include
adolescence, advanced age,
and gender; Box 6
1For details, see ICON: Anaphylaxis text page 5 and references 2, 3, and 4, including the tables, figures, and boxes from these references that are mentioned above
in this Table.
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They all recommend positioning the patient supine (or
semi-reclining in a position of comfort if dyspneic or
vomiting) with elevation of the lower extremities [2-4].
The guidelines also concur that if indicated at any time,
supplemental oxygen, intravenous (IV) fluid resuscitation
with a crystalloid such as 0.9% (isotonic) saline, and cardio-
pulmonary resuscitation should be started without delay
[2-4] and that H1-antihistamines, H2-antihistamines, and
glucocorticoids are not initial medications of choice [72-75].
There are a few differences in emphasis among the
guidelines with regard to initial treatment of anaphylaxis.
The WAO Guidelines include the revised resuscitation
guidelines recommendations for starting cardiopulmo-
nary resuscitation with chest compressions before giving
rescue breaths, allowing time for complete chest recoil,
and minimizing interruptions for pulse checks [2,76].
The WAO Guidelines and AAAAI/ACAAI Guidelines
describe epinephrine injection, calling for help, and posi-
tioning the patient appropriately as concurrent initial
steps [2,3], while the EAACI Guidelines describe epi-
nephrine injection as a first-line intervention and calling
for help and positioning as second-line interventions [4].
The WAO Guidelines and the AAAAI/ACAAI Guide-
lines do not specifically recommend inhaled epinephrine
for patients with stridor during anaphylaxis, although
they note that an inhaled beta-2 agonist should be con-
sidered in patients with bronchospasm that persists des-
pite epinephrine treatment [2,3]. The EAACI Guidelines
recommend inhaled epinephrine (adrenaline) in patients
with stridor and an inhaled beta-2 adrenergic agonist in
patients with wheezing after, and in addition to, epineph-
rine injection [4] (Table 4).
None of the guidelines discuss epinephrine injection in
high-risk patients after exposure to a relevant trigger but
Table 4 Anaphylaxis treatment in healthcare settings: summary of collaborating organizations’ principal anaphylaxis
guidelines1
WAO Guidelines AAAAI/ACAAI2 Guidelines EAACI3 Guidelines
Prompt initial treatment
of anaphylaxis
have a protocol; remove the
trigger, if relevant, assess rapidly,
promptly and simultaneously call
for help, inject epinephrine IM,
repeat in 5-15 min, position the
patient supine (semi-reclining if
dyspneic or vomiting) with lower
extremities elevated; Tables 5, 6,
7; Figure 4
epinephrine IM is the initial
medication of choice; repeat
in 5+ min; have a protocol;
remove exposure to the trigger;
position the patient supine
(semi-reclining if dyspneic or
vomiting) with lower extremities
elevated; call for help; Figures
E2, E3
1st-line treatment: inject
epinephrine IM; repeat in
10 min; 2nd-line treatment:
inhaled beta-2 agonists for
wheezing; inhaled adrenaline
for stridor; remove the trigger,
call for help, position the patient
appropriately, high-flow oxygen,
fluid support (crystalloid); Boxes
7, 8, 15; online supplement; Figure 2
Initial treatment (cont.) when indicated, give supplemental
high-flow oxygen; IV fluids (crystalloid);
start cardiopulmonary resuscitation
with continuous chest compressions;
H1- and H2-antihistamines, beta-2
agonists, and glucocorticoids are
2nd-line medications; Tables 5, 6, 7, 8;
Figure 4
supplemental oxygen; IV fluid
(crystalloid or colloid);
cardiopulmonary resuscitation;
H1- and H2-antihistamines, inhaled
beta-2 agonists, and glucocorticoids
are not initial medications of choice;
Figures E2, E3
3rd-line interventions: H1- and
H2-antihistamines, glucocorticoids;
protocol for initial management
includes cardiopulmonary
resuscitation; systematic review of
emergency management; Boxes
7, 15; online supplement; Figure 2
Management of refractory
anaphylaxis
intubation; ventilation; IV vasopressors;
glucagon; anticholinergic; transfer to
hospital (preferably to an emergency
medicine, critical care medicine, or
anesthesiology) team for ventilatory
and inotropic support; checklist of
needed items; Table 6
vasopressors; dopamine; give
vasopressin if epinephrine injections
and volume expansion fail to
alleviate hypotension; transfer to
hospital; glucagon; atropine;
methylene blue; includes checklist
of supplies and equipment;
Figures E2, E3
glucagon
Observation and
monitoring in healthcare
settings
observe for minimum 4 hrs; 8-10 hrs
if respiratory or cardiovascular
compromise; monitor BP, cardiac rate
and function, respiratory status and
oxygenation at frequent regular intervals,
eg. 1-5 mins; continuous electronic
monitoring if possible (essential if giving
vasopressors); Table 5; Figure 4
individualize duration of observation;
monitor BP and heart rate at frequent
regular intervals (eg. 1 minute);
continuous monitoring of BP, heart
rate and function, and oxygenation, if
possible; an example of a treatment
record form for use in patients with
anaphylaxis is provided; Figures E2, E4
minimum duration of observation
6-8 hrs for patients with respiratory
symptoms and 12-24 hrs for those
with hypotension or collapse; need
for monitoring is highlighted;
Box 7; online supplement;
Figure 2
1For details, see ICON: Anaphylaxis text pages 5-8 and references 2, 3, and 4, including the tables, figures, boxes, and online supplemental materials from these
references that are mentioned above in this Table.
2In the AAAAI/ACAAI Practice Parameters, one algorithm describes initial evaluation and management of a patient with a history of a previous episode of
anaphylaxis and another algorithm describes treatment of an anaphylactic event in the outpatient setting.
3An evidence-based review of effectiveness of interventions for acute and long-term management is published separately.
BP, blood pressure; IM, intramuscular; IV, intravenous.
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before symptoms develop and none discuss epinephrine
administration to a patient diagnosed incorrectly with
anaphylaxis, perhaps because there is little or no pub-
lished information on either of these issues.
Epinephrine utilization in anaphylaxis remains an active
area of research. The need for prompt epinephrine use to
prevent escalation of mediator release in anaphylaxis has
been confirmed in a new in vitro model [77]. Use of mul-
tiple epinephrine injections does not necessarily correlate
with patient obesity [78]. Rates of epinephrine utilization
as the initial medication for anaphylaxis in emergency de-
partments are typically low [79]; however, they can be im-
proved significantly with implementation of an anaphylaxis
protocol [80,81].
Management of anaphylaxis refractory to initial treatment
The guidelines differ in emphasis on refractory anaphylaxis
treatment. The WAO Guidelines stress the importance of
prompt initial treatment to prevent escalation of symptoms
[2]. They suggest that if possible, patients with anaphylaxis
refractory to epinephrine, supplemental oxygen, IV fluids,
and second-line medications should be transferred to the
care of a specialist team for ventilatory and inotropic
support and continuous electronic monitoring [2]. The
AAAAI/ACAAI Guidelines provide details about interven-
tions for cardiopulmonary arrest, airway management, and
IV administration of vasopressors including epinephrine,
dopamine, and vasopressin [3]. The EAACI Guidelines in-
clude brief specific instructions about when to call for In-
tensive Care Unit support [4] (Table 4).
Studies relevant to refractory anaphylaxis treatment
are of interest. A Cochrane review of randomized con-
trolled trials (RCT) in more than 20,000 critically ill pa-
tients with distributive shock supports administration of
crystalloids such as 0.9% saline, because administration
of colloids such as albumin or hetastarch did not
Table 5 Anaphylaxis in community settings: summary of collaborating organizations’ principal anaphylaxis guidelines1
WAO Guidelines AAAAI/ACAAI Guidelines EAACI Guidelines
Post-discharge management of
patients treated for acute
anaphylaxis
prescribe epinephrine IM
through auto-injector; anaphylaxis
emergency action plan; medical
ID stating triggers and
co-morbidities; Table 9, Figure 5
prescribe epinephrine IM through
auto-injector; anaphylaxis emergency
action plan; medical ID; “an action
plan is an important component of
follow-up”; Figure E1
prescribe epinephrine IM through
auto-injector; provide discharge
advice sheet; provide specialist
referral and contact information
for patient support groups; Boxes
7, 9, 10, 11, 12, 13, 14, 15
Investigations by allergy/
immunology specialists to
confirm anaphylaxis triggers
state the importance of the
history of the episode; describe
skin prick tests (intradermal tests
needed for venom and
drug-triggered anaphylaxis);
investigations in idiopathic
anaphylaxis; additional tests
when needed to distinguish
allergen sensitization from clinical
risk in patients with food or
drug allergy; Table 9, Figure 5
describe investigations in detail
under different triggers; describe
investigations in idiopathic
anaphylaxis; details on skin testing
with anesthetic agents; Table E8
state “validated in vivo and/or in
vitro tests should be interpreted
in the light of a detailed allergy
history”; additional information re
investigations to confirm food
triggers is published separately in
the EAACI Food Allergy Guidelines
Prevention of anaphylaxis
recurrences
describe allergen avoidance (food,
stinging insects, drugs, latex, etc.);
immunotherapy with standardized
insect venoms; and desensitization
to drugs; mention food OIT2;
describe pharmacologic prophylaxis
of RCM anaphylaxis and idiopathic
anaphylaxis; Table 9, Figure 5
describe specific avoidance measures
under triggers; describe venom
immunotherapy and desensitization
to drugs; describe pharmacologic
prophylaxis of RCM anaphylaxis and
idiopathic anaphylaxis; Table E6;
Figure E1
describe food avoidance; venom
immunotherapy and desensitization
to drugs; mention food OIT2;
describe pharmacologic prophylaxis
of anaphylaxis to RCM and snake
anti-venom; Boxes 8, 9, 15; online
supplement
Anaphylaxis education and
training
outline principles of anaphylaxis
education
provide relevant information under
various triggers; give examples of
print resources; Figure E1
major emphasis on all aspects of
anaphylaxis training and adrenaline
auto-injector prescription; Boxes 9, 10,
11, 12, 13, 14, 15; online supplement
Follow-up with physician yearly review of EAI use, action plan,
optimal management of co-morbid
diseases, adjustment of concurrent
medications as needed, allergen
avoidance, and immune modulation
review discharge management,
allergen avoidance, and immune
modulation
major emphasis; include
recommendations for training,
management plan, and if relevant,
help from nutritionists and
psychologists; Boxes 9, 15; online
supplement
1For details, see ICON: Anaphylaxis text pages 8-9 and references 2, 3, and 4, including the tables, figures, boxes, and online supplemental materials from these
references that are mentioned above in this Table.
2Described but not recommended for clinical implementation at this time.
EAI, epinephrine auto-injector; ID, identification; IM, intramuscular; OIT, oral immunotherapy; RCM, radiocontrast media.
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correlate with increased survival [82]. Methylene blue
administration for vasoplegia in anaphylaxis refractory
to epinephrine and IV fluid resuscitation is based on
case reports and extrapolation from use in other forms
of shock [83].
Observation and monitoring in healthcare settings
The guidelines concur that patients with moderate or se-
vere anaphylaxis, for example, those with moderate or
severe respiratory or cardiovascular symptoms and signs
should be observed and monitored for a longer duration
(eg. at least 6-8 hours) than those with mild anaphylaxis.
The WAO Guidelines note that duration of monitoring
can also vary with patient age and co-morbidities,
and with local conditions. The AAAAI and EAACI
Guidelines provide additional information about bi-
phasic anaphylaxis and protracted anaphylaxis [2-4]
(Table 4).
In a prospective study in which mediator release in
anaphylaxis was documented at sequential timed inter-
vals, levels of some mediators correlated with delayed
deterioration, supporting recommendations for safe ob-
servation periods after initial treatment [24].
The guidelines also concur that blood pressure, cardiac
rate and function, respiratory status and oxygenation
should be monitored clinically at frequent intervals
(every 1-5 minutes), or if possible, continuously [2-4].
Lack of universal availability of continuous electronic
monitoring and pulse oximetry remains a concern.
Post-discharge management of patients treated for acute
anaphylaxis
Collaborating organizations’ guidelines concur that man-
agement of anaphylaxis does not end with treatment of
the anaphylactic episode [2-4] and that post-discharge
management should include follow-up with a physician,
preferably an allergy/immunology specialist [2,4,84-124]
(Table 5).
The WAO Guidelines state that if epinephrine auto-
injectors are not available, alternative, although not pre-
ferred, recommendations for epinephrine injection need to
be provided (for details, please see the subsequent section
on Post-Discharge Management on page 12 of this paper)
[2,6,7]. They also note the importance of anaphylaxis
emergency action plans and medical identification (ID)
stating anaphylaxis triggers and co-morbid diseases. The
AAAAI/ACAAI Guidelines recommend prescribing more
than one epinephrine auto-injector because more than
one dose of epinephrine is needed in about 20% of ana-
phylactic episodes; additionally, they recommend action
plans and medical ID [3]. The EAACI Guidelines include
comprehensive information about discharge manage-
ment, for example, providing a discharge letter for the
family doctor, as well as providing a discharge sheet for
patients that contains information about epinephrine
auto-injector use, allergen avoidance, and how to contact
patient support groups. They also include detailed infor-
mation about management plans, evidence-based absolute
indications for prescription of at least one auto-injector,
and suggested indications for prescription of a second
auto-injector. They suggest strategies for training patients
at risk and caregivers of patients at risk. Additionally, they
list gaps in the evidence supporting recommendations for
long-term management of anaphylaxis [4] (Table 5).
Post-discharge management of patients at risk for ana-
phylaxis recurrences in the community is an active area
of research [84-98]. This focuses on patient and care-
giver failure to carry auto-injectors and use auto-
injectors for anaphylaxis [87,88], patient, caregiver, and
physician experiences in using auto-injectors [89-92],
auto-injector redesign [93,94] and education and support
of patients at risk [95-97], an area in which additional
high-quality studies are needed [98]. Although improved
rates of filling epinephrine prescriptions after discharge
from some emergency departments are reported [85,86],
for many patients lack of affordable auto-injectors re-
mains a barrier to use [7].
Investigations to confirm anaphylaxis triggers
The guidelines concur that triggers should be confirmed
by re-taking the history of the anaphylactic episode
and using this as a guide to selection of allergens for
skin prick tests, measurement of allergen-specific IgE
levels in serum, and additional investigations as needed
[2-4,13-15,22,53,99-106]. Intradermal tests are helpful in
investigation of anaphylaxis induced by insect venoms or
drugs such as beta-lactam antibiotics [103-106]. Negative
skin tests and absent or undetectable allergen-specific IgE
levels have a high negative predictive value; however, posi-
tive tests have a lower positive predictive value because
allergen sensitization without symptoms is widespread
in the general population. Ideally, tests to assess sensitization
to allergens should be interpreted by an allergy/immunology
specialist [2-4,13-15,22,53,64,99-106] (Table 5). Medically-
supervised incremental allergen challenge tests, indi-
cated in some patients with food or drug allergy, should
be conducted only by experienced healthcare profes-
sionals in settings where anaphylaxis can be treated
promptly [2-4,13,15,22,53,104,105].
None of the guidelines emphasize standardization of
tests and challenges; perhaps because international con-
sensus documents on standardization were only pub-
lished in 2012 and 2013 [2-4,100,102].
Prevention of anaphylaxis recurrences
The guidelines concur about prevention of anaphylaxis re-
currences by avoidance of confirmed allergens, including
hidden or cross-reacting allergens [2-4,13-15,22,53,64,99,
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104,105,107-111]. Vigilant avoidance prevents anaphylaxis
recurrence from culprit allergens [107,108]; however, it
can be time-consuming, frustrating, difficult to sustain in
daily life, and associated with impaired quality-of-life; in-
cluding bullying of food-allergic children [109-111].
The guidelines concur in their recommendation for im-
mune modulation to prevent recurrences of anaphylactic
episodes from stinging insect venom [2-4,14,112-116]
and drugs [2-4,15,117]. The WAO Guidelines and
EAACI Guidelines describe oral immunotherapy (OIT)
to prevent recurrences of food-induced anaphylaxis,
but concur that this approach is not yet ready for gen-
eral use [2,4,13,22,119] (Table 5).
For prevention of recurrence of stinging insect venom-
induced anaphylaxis, a 3-5 year course of subcutaneous
immunotherapy with the relevant standardized specific
venom(s) leads to long-lasting protection in most patients
[2-4,14,112-115]; lifelong venom immunotherapy (VIT) is
recommended in patients with mastocytosis [116].
For prevention of recurrent anaphylaxis from a drug
such as an antibiotic or NSAID, or a biologic agent, when
no safe substitute is available, desensitization conducted
by experienced healthcare professionals using a published
protocol is safe and effective for one uninterrupted course
of treatment [2-4,15,104,105,117].
In carefully selected patients with symptoms after in-
gestion of milk, egg, peanut, or other highly allergenic
food, RCT of OIT confirm that clinical desensitization
can be achieved in most patients; however, sustained un-
responsiveness after stopping treatment is more difficult
to achieve, and adverse events, including anaphylaxis,
occur [99,119,120]. OIT safety can be improved with
omalizumab pre-treatment and co-treatment [99,121].
Sublingual immunotherapy to prevent food-induced
anaphylaxis, although less effective than OIT, is associ-
ated with fewer adverse events [99,120].
The guidelines differ in their emphasis on pharmacologic
prophylaxis of anaphylaxis from various triggers. They all
describe pharmacologic interventions to prevent anaphyl-
axis to radiocontrast media [2-4,64,122]. The WAO and
the AAAAI/ACAAI Guidelines recommend pharmacologic
prophylaxis in selected patients with idiopathic anaphylaxis
[2,3]. The EAACI Guidelines provide information about
pretreatment with epinephrine to prevent anaphylaxis to
snake anti-venom [4,123]. Surprisingly, no guidelines pro-
vide information about pharmacological prophylaxis of ana-
phylaxis from subcutaneous allergen immunotherapy,
although H1-antihistamine pre-treatment before venom in-
jections during VIT reduces systemic adverse events and
has a beneficial immune-modifying effect [124] (Table 5).
Anaphylaxis education
The guidelines differ in their emphasis on anaphylaxis edu-
cation for patients and caregivers. The WAO Guidelines
outline the principles of anaphylaxis education [2]. The
AAAAI/ACAAI Guidelines discuss anaphylaxis education
in the context of some specific triggers [3]. The EAACI
Guidelines provide comprehensive information about ana-
phylaxis education, including information about long-term
management, recommendations for training (with descrip-
tion of barriers to and facilitators of implementation), audit
criteria, and resource implications [4] (Table 5).
None of the guidelines describe anaphylaxis education
for personnel working in child care, schools, colleges,
universities, summer camps, and sports facilities, or the
hospitality or airline industries; however, a forthcoming
EAACI publication addresses anaphylaxis education in
the community-at-large (Muraro A, personal communication).
Follow-up with a physician
All the guidelines address the issue of follow-up with a
physician [2-4], if possible with an allergy/immunology
specialist. The WAO Guidelines recommend follow-up
yearly for review of prevention of recurrence, epineph-
rine auto-injector use, and optimizing control of relevant
co-morbid diseases such as asthma [2]. The AAAAI/
ACAAI Guidelines discuss specific aspects of follow-up
in association with some of the major triggers [3]. In
addition to physician follow-up, the WAO and EAACI
Guidelines note the importance of follow-up with a diet-
ician, if relevant, and the EAACI Guidelines also suggest
follow-up with a psychologist, if relevant [4] (Table 5).
Unmet needs in anaphylaxis
Unmet needs in anaphylaxis in high-, mid-, and low-
resource countries are described in Tables 6, 7, 8, and 9.
Definition of anaphylaxis
In all countries, increased awareness of anaphylaxis as a
serious, life-threatening, generalized or systemic, allergic
or hypersensitivity reaction with sudden onset (minutes
to a few hours) is needed among healthcare profes-
sionals, patients, caregivers, and the public (Table 6).
Epidemiology
For epidemiologic purposes, the validated clinical criteria
for anaphylaxis diagnosis are helpful for informing Inter-
national Classification of Disease (ICD)-9 and ICD-10
codes and facilitating reliable estimates of anaphylaxis
prevalence in healthcare settings [27-33] and to a lesser
extent in the general population [34,35].
In all countries, epidemiological and health services re-
search can serve as a baseline for quality improvement,
prioritization of anaphylaxis programs, and eventual re-
duction in morbidity and mortality. However, until diag-
nosis of anaphylaxis as such by healthcare professionals
improves and recognition by patients, caregivers, and
the public improves, it will remain difficult to obtain
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reliable epidemiologic information about anaphylaxis and
its prevalence will remain under-estimated (Table 6).
At post-mortem, too, anaphylaxis can be under-diagnosed
[36]; for example, when signs of anaphylaxis are absent
and recognition is based only on circumstantial evi-
dence and exclusion of other diseases [37]. Nevertheless,
anaphylaxis fatality studies can sometimes provide unique
information about triggers, presenting symptoms and
signs, time course, and associated co-morbidities in a spe-
cific region or country.
Patient-specific risk factors and co-factors relevant to
anaphylaxis
In all countries, improved recognition of patient vulner-
ability to anaphylaxis is needed as related to age, physio-
logic state (pregnancy), concomitant diseases, concurrent
medications, and amplifying co-factors. In some countries,
the prevalence of co-morbid diseases such as asthma or
CVD might itself not be known (Table 6).
Underlying mechanisms and anaphylaxis triggers
Positive collaborations among physicians in academic
centers and national allergy/immunology professional
organizations in high-resource countries with those in
mid- or low-resource countries are expanding our global
knowledge of anaphylaxis mechanisms and triggers
[36,37,56,57,123]. Despite this, in some countries, little
information about anaphylaxis triggers, even the tax-
onomy of indigenous food plants and stinging insects, is
available. Where potential triggers remain unidentified,
lack of context for recognition of anaphylaxis can delay
diagnosis and treatment (Table 6).
Clinical diagnosis of anaphylaxis
In all countries, improved training of healthcare profes-
sionals to recognize and treat anaphylaxis is needed, and
the validated clinical criteria for anaphylaxis diagnosis
need to be operationalized in order to optimize their
usefulness. Where resources are limited, there can be in-
consistent availability of basic services such as electricity
and of equipment and supplies that aid in anaphylaxis
diagnosis; for example, pulse oximeters to document
oxygenation and sphygmomanometers and arm cuffs of
various sizes to document blood pressure [125-130].
In such situations, assessment of hypoxemia is based
on clinical indicators such as central cyanosis, nasal flar-
ing, inability to speak or drink, grunting, lethargy, severe
chest retractions, respiratory rate of more than 70
breaths/minute, and head-nodding; a capillary refill time
of 2 seconds or less is documented to reflect a superior
Table 6 Essential information on anaphylaxis: summary of unmet needs
High-resource countries1 Limited-resource countries2
Definition of anaphylaxis, eg. serious,
life-threatening generalized allergic
or hypersensitivity reaction
need ↑ awareness of a current anaphylaxis
definition for clinical use
need ↑ awareness of a current
anaphylaxis definition for
clinical use
Epidemiology need integration of the clinical criteria for
diagnosis of anaphylaxis with ICD-9 and
ICD-10 codes; need more reliable prevalence
estimates in healthcare settings and in the
general population; and need more reliable
prevalence estimates of mortality rates
from different triggers in different patient
populations
need concurrent epidemiologic
studies of anaphylaxis using similar
methods in different countries in order
to obtain reliable prevalence estimates
in the general population
Patient risk factors and co-factors
relevant to anaphylaxis
need ↑ awareness of patient risk factors for
severe or fatal anaphylaxis, eg. asthma, CVD
and MCAD; and need ↑ awareness of the
role of co-factors such as exercise, ethanol,
NSAIDs, emotional stress, acute infection,
perimenstrual status
need baseline information about the
prevalence of asthma, CVD, and MCAD
so their relationship with anaphylaxis
can be ascertained; need ↑ awareness
of potential patient risk factors and
co-factors; insights might be obtained
from studies of fatal episodes3
Underlying mechanisms need greater understanding of IgE-dependent,
IgE-independent, and non-immunologic
mechanisms (direct mast cell activation)
need greater understanding of
IgE-dependent, IgE-independent, and
non-immunologic mechanisms
Triggers (causes, elicitors, or inducers) need improved standardization of allergens, a
standardized mechanism for reporting novel
triggers, and continued efforts to standardize
protocols for skin tests and challenge tests
need more comprehensive information
about newly-discovered allergen triggers,
allergens in some geographic areas, and
certain groups of allergens, eg. reptile
venoms and helminths
1Within high-resource countries, limited-resource areas can be found in inner cities, some rural areas, many public venues, and situations such as anaphylaxis
on airplanes.
2In this Table, “limited-resource countries” include mid- and low-resource countries.
3In some limited-resource countries, fewer than 5% of deaths are certified with regard to cause.
CVD, cardiovascular disease; ICD, International Classification of Disease; MCAD; mast cell activation disorders; NSAIDs, non-steroidal anti-inflammatory drugs.
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vena caval oxygen saturation of greater than 70%. As-
sessment of hypotension and distributive shock is based
on clinical indicators such as weak or non-palpable per-
ipheral pulses [125-127] (Table 7).
In all countries, in the differential diagnosis of ana-
phylaxis, healthcare professionals should be aware of
common considerations such as acute asthma, acute ur-
ticaria, and panic or anxiety attacks. In some countries,
pneumonia is the most common consideration in pa-
tients presenting with acute-onset respiratory distress
and hypoxemia, and sepsis is the most common consid-
eration in those presenting with acute-onset hypotension
or shock [2-4,125,126] (Table 7).
Prompt initial treatment of anaphylaxis and monitoring
In all countries, at the onset of an anaphylactic episode, it
can be impossible to predict the rate of escalation or reso-
lution of symptoms. Patients can present with deceptively
mild symptoms such as hives, cough, or dizziness that
rapidly increase in severity and culminate in fatality
within minutes. Regardless of available resources, an
important message to healthcare professionals, patients,
caregivers, and the public is to recognize anaphylaxis
promptly and as soon as it is recognized, inject life-
saving epinephrine in order to maximize the likelihood
of survival [2-4].
Box: The essentials of prompt initial anaphylaxis
treatment
- have an easy-to-follow and well-rehearsed protocol
- remove exposure to the trigger, if relevant
- inject epinephrine promptly intramuscularly in the
mid-outer thigh
- call for help (resuscitation team in hospital or
emergency medical services in community,
if available)
- position the patient supine (or semi-reclining in a
position of comfort if dyspneic or vomiting) and
elevate the lower extremities
If indicated at any time,
- provide supplemental oxygen
- initiate IV fluid resuscitation with 0.9% saline
- perform cardiopulmonary resuscitation
- monitor BP, cardiac rate and function, and oxygen
saturation
See Table 8 for details.
Where resources are limited, supplemental oxygen can
be provided by oxygen concentrators instead of oxygen
cylinders, and nasal prongs or nasopharyngeal catheters
can be substituted for oxygen masks [128,129]; however,
Table 7 Diagnosis of anaphylaxis: summary of unmet needs
High-resource countries1 Limited-resource countries2
Symptoms and signs (typically
with onset in minutes to a few
hours after exposure; multi-system;
rapid progression)
need improved recognition and diagnosis
of anaphylaxis and its sudden onset in
relationship to exposure to a trigger (the
context) among all healthcare professionals
(including EMS personnel), patients, caregivers
and the public
need improved recognition and diagnosis of
anaphylaxis and its sudden onset in relationship
to exposure to a trigger (the context) among all
healthcare professionals, patients, caregivers, and
the public
Clinical diagnosis of anaphylaxis need to operationalize the clinical criteria
for the diagnosis of anaphylaxis by healthcare
professionals; need improved coding for
anaphylaxis and training of coders
need to operationalize the clinical criteria for the
diagnosis of anaphylaxis; need ↑ availability of
basic equipment and supplies to aid in recognition,
eg. pulse oximetry and sphygmomanometers
with arm cuffs of various sizes
Laboratory tests to confirm the
clinical diagnosis eg. serum total
tryptase measurement3
need ↑ awareness of optimal timing of tests,
and lack of test specificity (eg. ↑ tryptase in
some patients with MI); need ↑ awareness that
current lab tests are not useful at the time of
patient presentation; need ongoing
development of tests for biologic markers
need awareness that inability to measure tryptase
levels (which is unlikely to be a priority for change
due to high cost) is not a barrier to prompt
diagnosis of anaphylaxis, which depends on
recognition of symptoms and signs
Differential diagnosis need ↑ awareness that among the >40 entities
in the differential diagnosis, acute asthma,
acute urticaria, and panic or anxiety attacks are
most common
need awareness that in some countries, pneumonia
and sepsis are the most likely diagnoses in patients
with sudden-onset respiratory distress and sudden-
onset hypotension/ distributive shock, respectively
Diagnosis of anaphylaxis in
special populations
need improved prompt recognition of
anaphylaxis in infancy, adolescence, pregnancy,
and advanced age
need improved prompt recognition of anaphylaxis in
infancy, adolescence, pregnancy, and advanced age
1Within high-resource countries, limited-resource areas can be found in inner cities, some rural areas, many public venues, and situations such as anaphylaxis
on airplanes.
2In this Table, “limited-resource countries” include mid- and low-resource countries.
3The tryptase assay is standardized worldwide; in contrast, histamine assays are not standardized and are less practical for clinical use because of the need to
refrigerate specimens.
EMS, emergency medical services; MI, myocardial infarction.
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in many hospitals, lack of availability of pulse oximetry for
detecting hypoxemia and guiding oxygen therapy remains
a critical concern [127]. Despite best efforts, treatment of
anaphylaxis can, in some patients, be compromised by co-
morbidities such as anemia and reduced ability to achieve
adequate oxygenation, or severe malnutrition and reduced
ability to tolerate IV fluid resuscitation [125,126] (Table 8).
Management of anaphylaxis refractory to initial treatment
Even in high-resource countries, optimal treatment of re-
fractory anaphylaxis is not available universally; for ex-
ample, in remote, inaccessible, or impoverished areas or in
specific situations such as anaphylaxis on airplanes. In
limited-resource situations, lack of availability of basic es-
sentials such as epinephrine, supplemental oxygen and IV
fluid resuscitation is more critical than lack of second-line
medications such as antihistamines and glucocorticoids.
Lack of availability of advanced life-support management
can be a major barrier to survival [72-76,128] (Table 8). In
any limited-resource situation, resuscitation efforts pro-
longed over hours using a hand-held bag valve mask
(manual resuscitator) are often successful in anaphylaxis
[2] (Table 8).
In mid- and low-resource countries, striving to ensure
more consistent availability of medications, supplies, and
equipment for anaphylaxis treatment is an important
goal [2,5-7]. The World Health Organization has devel-
oped a tool kit containing evidence-based guidelines and
a framework for quality improvement in the hospital
care of critically ill children in such environments [126],
where despite many obstacles, improvements can be
documented [130].
Post-discharge management
In high-resource countries, there is an increased focus on
post-discharge management after successful treatment of
anaphylaxis. Where resources are limited, post-discharge
management is severely compromised by lack of availability
of affordable auto-injectors or factory-sealed prefilled syrin-
ges containing epinephrine [2,6,7]. There are two alterna-
tive, although not preferred, options for epinephrine self-
administration. First, a 1 mL ampule of epinephrine and a
1 mL syringe can be provided; however, in a medical emer-
gency, patients without medical training find it difficult to
draw up a dose accurately and expel air from the syringe
without losing the epinephrine. Second, an unsealed pre-
filled syringe containing the correct dose for the patient can
be drawn up in advance by his/her physician; however, all
or part of the dose can be lost, and epinephrine is stable for
only 3-4 months in an unsealed syringe [2,6,7].
Where resources are limited, local conditions typically
determine the availability of follow-up with a healthcare
professional and prevention of recurrent anaphylactic
episodes is often compromised by lack of availability of
physicians, tests to confirm triggers, and immune modu-
lation (Table 9).
Table 8 Treatment of anaphylaxis in healthcare settings: summary of unmet needs
High-resource countries1 Limited-resource countries2
Prompt initial treatment of
anaphylaxis
need to encourage the “be prepared”
approach: have a protocol, inject
epinephrine promptly IM in mid-outer
thigh, call for help, and position the patient
appropriately; need to reduce the fear factor
associated with epinephrine use by stressing
the good benefit/harm ratio of prompt IM
epinephrine compared with IV epinephrine
need to develop simple protocols, and focus on essentials:
inject epinephrine promptly IM in mid-outer thigh, call for
help, position the patient appropriately; need to ensure the
availability of epinephrine as an essential drug in 1 mg/mL
ampules in all healthcare facilities, and improve availability of
low-cost EAIs (or if EAIs are unaffordable, factory-sealed
syringes prefilled with epinephrine 1 mg/mL)
Initial treatment (cont.) need ↑ awareness that H1-antihistamines,
H2-antihistamines, and glucocorticoids are
not initial medications of choice in anaphylaxis
and should not be used as monotherapy
need ↑ availability of supplemental oxygen and IV fluids;
where oxygen cylinders are not available, oxygen
concentrators can be useful; lack of availability of
supplemental oxygen and IV fluids is more critical than lack
of second-line medications such as antihistamines and
glucocorticoids, which are not essential for survival
Management of anaphylaxis refractory
to initial treatment
need to identify hospitals where patients
with refractory anaphylaxis can receive skilled
ventilatory and inotropic support from
experienced, well-equipped personnel, and to
list the contact information for these facilities
on the anaphylaxis protocol
need ↑ availability of supplemental oxygen
and IV fluids such as 0.9% saline; need regular
reassessment of availability of epinephrine,
supplemental oxygen and IV fluids, supplies
and equipment in hospitals
Observation and monitoring in
healthcare settings
need ↑ availability of continuous electronic
monitoring of cardiac rate, function, and
blood pressure, and of pulse oximetry
need ↑ availability of basic supplies and equipment for
monitoring in many hospitals; and improved availability of
continuous electronic monitoring of cardiac rate, function,
and blood pressure, and pulse oximetry in teaching hospitals
1Within high-resource countries, limited-resource areas can be found in inner cities, some rural areas, many public venues, and situations such as anaphylaxis
on airplanes.
2In this Table, “limited-resource countries” include mid- and low-resource countries.
EAIs, epinephrine auto-injectors; IM, intramuscular; IV, intravenous.
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International research agenda for anaphylaxis
Anaphylaxis research has been hindered in the past by
the perception that the disease is rare, absence of a uni-
versally accepted definition for clinical use, and lack of
validated criteria for anaphylaxis diagnosis suitable for
use in clinical and epidemiologic studies. Progress in
these areas is giving momentum to basic, translational,
and clinical anaphylaxis research.
ICON: Anaphylaxis proposes a comprehensive inter-
national research agenda for anaphylaxis (Tables 10 and
11) that extends and amplifies the anaphylaxis research
agendas published independently by WAO and EAACI
[2,4]. The ICON: Anaphylaxis research agenda is based in
part on identification of areas where little or no high qual-
ity evidence is available to support the recommendations
for anaphylaxis diagnosis, treatment, and prevention made
in anaphylaxis guidelines and other publications.
Research tasks awaiting prioritization, as listed in
Table 10, include operationalizing the clinical criteria
for diagnosis and additional studies of epidemiology, pa-
tient risk factors, mechanisms, and triggers. Research
tasks awaiting prioritization, as listed in Table 11,
include further RCT of interventions, risk assessment,
long-term risk reduction, and anaphylaxis education, as
well as studies on anaphylaxis guidelines implementation
and development of anaphylaxis pathways.
The ICON: Anaphylaxis research agenda will require
regular updating and might take decades to complete,
depending on the collaborations initiated and the finan-
cial support available. Prioritization of research ques-
tions is recommended. Initially this should involve
identification of questions that are feasible to answer in
the short-to-medium term, ideally guided by a formal
consensus-building process involving basic scientists,
methodologists, and clinician scientists.
Global collaborative efforts to date are improving the
diagnosis and treatment of anaphylaxis [36,37,56,57,123].
They have identified the importance of using the validated
clinical criteria to inform ICD-10 codes for improved accur-
acy of anaphylaxis identification at autopsy [36], and found
differences between culprit allergens and circumstances of
death from anaphylaxis in different countries [37]. They
have also elucidated the role of novel anaphylaxis
triggers, for example, flour mites [56] and short-chain
Table 9 Treatment of anaphylaxis in community settings: summary of unmet needs
High-resource countries1 Limited-resource countries2
Discharge management of patients
treated for anaphylaxis
need ↑ public awareness of the importance
of prompt anaphylaxis recognition and
first-aid treatment for patients with anaphylaxis
in the community; need ↑ availability of
low-cost EAIs and of “stock” epinephrine3 in
schools, shopping malls, etc.; need a wider
range of epinephrine doses in auto-injectors,
eg. 0.1 mg and 0.5 mg
need ↑ availability of low-cost EAIs or even
factory-sealed prefilled epinephrine syringes;
need ↑ awareness of alternative but not
preferred options (epinephrine 1 mg/1 mL
ampules and 1 mL syringes, and unsealed
syringes prefilled by healthcare professionals);
need more information about epinephrine
shelf-life in extreme climates
Investigations to confirm anaphylaxis
triggers
need improved standardization of allergens and
of test and challenge protocols; need ↑ awareness
that allergen sensitization is far more common than
clinical symptoms; and that tests for sensitization
must be selected and interpreted based on the
history of the anaphylactic episode
need ↑ awareness that if sterile needles are
available, allergen skin tests can be performed
by skin prick or prick-prick testing with relevant
foods, or skin testing with IV formulations
of medications
Prevention of anaphylaxis recurrences need improved public policies with regard
to food labeling, improved school policies for
anaphylaxis prevention and treatment, and
improved access to specialists, including
those who can document sensitization to
novel triggers
need improved training of healthcare professionals
to identify anaphylaxis triggers, symptoms, and signs;
need ↑ availability of tests to confirm sensitization;
(in their absence, trigger avoidance is based on the
history); need ↑ availability of venom immunotherapy
and desensitization to drugs
Anaphylaxis education need ↑ availability of personalized anaphylaxis
education by trained healthcare professionals
and development of personalized emergency
action plans that focus on recognition of
symptoms and signs, implementation of the
plan, prompt use of EAI, and wearing medical ID
need ↑ awareness of anaphylaxis, improved
training of healthcare professionals, and
development of action plans to aid in
recognition of anaphylaxis symptoms and
signs; need improved availability of EAIs
Follow-up need ↑ awareness of importance of follow-up
with an allergist/ immunologist to provide training
in anaphylaxis recognition, EAI use, allergen avoidance;
and when indicated, immune modulation, eg. VIT
need ↑ awareness of the importance of
follow-up after an acute anaphylactic episode;
availability of follow-up will depend on
local conditions
1Within high-resource countries, limited-resource areas can be found in inner cities, some rural areas, many public venues, and situations such as anaphylaxis on airplanes.
2In this Table, “limited-resource countries” include mid- and low-resource countries.
3Rationale: preventable deaths, especially in children, teenagers, and young adults occur in these venues; this issue is also listed in the research agenda (Table 11)
because of the need to gather additional data.
EAIs, epinephrine auto-injectors; ID, identification; VIT, venom immunotherapy.
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galacto-oligosaccharides [57], and confirmed in a RCT
that epinephrine pre-treatment reduced anaphylaxis
to anti-snake venom by 43% and was superior to
H1-antihistamine and glucocorticoid pre-treatment [123].
Global collaboration among investigators needs to be
facilitated in order to accelerate future advances.
Summary
ICON: Anaphylaxis presents a harmonized approach to
anaphylaxis diagnosis, treatment, and prevention based
on the alignment found in the collaborating organizations’
principal anaphylaxis guidelines. It documents consensus
in the critically important areas of clinical diagnosis,
Table 10 International research agenda for anaphylaxis1,2
Epidemiology, Patient Risk Factors, Mechanisms, Triggers, and Diagnosis
Epidemiology of anaphylaxis
Prospective studies of:
- global incidence and prevalence of anaphylaxis in general populations in different countries, in order to obtain reliable population estimates;
ideally, concurrent studies will be performed
- anaphylaxis from all triggers, and from specific triggers including foods, stinging insect and other venoms, drugs, etc.
- anaphylaxis in different populations: infants, children, teenagers, pregnant women, the elderly, and patients with co-morbidities such as asthma,
cardiovascular disease, and mast cell activation disorders
- the natural history of anaphylaxis based on well-designed longitudinal population-based investigations
Patient risk factors for anaphylaxis
Genotypes, phenotypes and endotypes of patients with anaphylaxis
Development of instruments to quantify patient-specific risk factors, ascertain their relative importance, and predict future anaphylactic episodes
Biologic markers for identification of patients at risk
Prospective studies of the relationship between food-induced anaphylaxis and asthma, in order to ascertain the relationship of anaphylaxis severity
and asthma control
Prospective studies of the relationship between food, insect venom, and drug-induced anaphylaxis and cardiovascular disease
Prospective studies of the relationship between anaphylaxis and mast cell activation disorders
Prospective studies of idiopathic anaphylaxis in patients of all ages
Anaphylaxis mechanisms
Further elucidation of mechanisms underlying anaphylaxis, including studies to improve understanding of molecular mechanisms
Studies of IgG-mediated anaphylaxis in humans
Additional studies of agents that can induce anaphylaxis through more than one mechanism, eg. radiocontrast media, biological agents such as
infliximab, etc.
Further elucidation of the role of amplifying co-factors in anaphylaxis
Triggers (causes, elicitors, inducers) of anaphylaxis
Prospective studies of trends in triggers, to identify those that are becoming more (or less) common in different patient populations and in different
global regions
Additional investigations of food cross-reactivities
Improved methods to detect hidden food allergens
Improved tests to confirm sensitization to anaphylaxis triggers that are uncommon in many countries, but relatively common in others; for example:
- foods such as buckwheat, silkworm pupa, bird's nest soup, chickpea, flour mites, maize, manioc
- stings and bites, eg. ants, caterpillars, jellyfish, lizards, scorpions, snakes
Diagnosis of anaphylaxis
Development of operationalized clinical criteria for the diagnosis of anaphylaxis
Validation of these operationalized clinical criteria for use in additional healthcare settings, in community settings, and in different countries
Development and validation of an algorithm for diagnosing anaphylaxis based on clinical criteria
Identification of additional biologic markers for identification of anaphylaxis
Further development of tests for biologic markers that might be useful for confirming the diagnosis of anaphylaxis at the time the patient presents
Development of protocols and algorithms to improve post-mortem identification of anaphylaxis as a cause of death
1Basic, clinical and applied sciences.
2This Table extends and amplifies the agendas for anaphylaxis research published independently by WAO and by EAACI.
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Table 11 International research agenda for anaphylaxis1,2
Management of Anaphylaxis in Healthcare and Community Settings, Risk Assessment and Reduction, and Education
Treatment in healthcare settings
Epinephrine pharmacokinetic and pharmacodynamic studies in patients with different body mass indices
Additional comprehensive studies of epinephrine absorption after different routes of administration, including auto-injectors
Additional observational investigations of the safety of a first-aid dose of epinephrine (0.3 mg intramuscularly) in patients with cardiovascular disease
Multicenter prospective randomized controlled trials to define the role of other pharmacologic interventions in anaphylaxis - examples include
H1-antihistamines, H2-antihistamines, glucocorticoids, and glucagon
Management in community settings
Additional comparative studies of different epinephrine auto-injectors
- preference to carry, preference to use, and rate of occurrence of unintentional injections and injuries
Evaluation of the role of “stock” or “unassigned” epinephrine auto-injectors in public places, eg. schools, shopping malls
Further assessment of costs of epinephrine auto-injectors and their cost-effectiveness
Further evaluation of other routes of epinephrine administration, eg. sublingual, inhaled, intranasal
Prospective validation studies of anaphylaxis emergency action plans
Comparison of different anaphylaxis emergency action plans
Assessment of effectiveness of anaphylaxis emergency action plans
Assessment of school plans for anaphylaxis
Risk assessment in anaphylaxis
Further standardization of allergens, allergen skin test protocols, and allergen challenge protocols to facilitate comparisons among centers
Further prospective studies of optimal timing of allergen skin tests after anaphylaxis to foods, venoms, drugs, and other allergens
Further development of in vitro tests such as component-resolved diagnostics and basophil activation tests to help distinguish asymptomatic
sensitization from clinical risk
Development of new non-invasive tests to assess sensitization versus risk of clinical reactivity to drugs
Long-term risk reduction in anaphylaxis
Further prospective investigations of efficacy and safety of oral, sublingual, and epicutaneous immunotherapy to prevent recurrence of
food-induced anaphylaxis and achieve immunologic tolerance
Further studies of the efficacy and safety of omalizumab pre-treatment and co-treatment with allergen immunotherapy
Studies of allergen immunotherapy to prevent anaphylaxis recurrences from less well-studied allergens, eg. natural rubber latex
Additional studies of immunotherapy to prevent recurrence of venom-induced anaphylaxis and immune modulation to prevent recurrence of
drug-induced anaphylaxis
Additional prospective investigations of pharmacologic prophylaxis of iatrogenic anaphylaxis from radiocontrast media, biologic agents, snake
anti-venom, allergen immunotherapy, etc.
Prospective investigations of the utility and cost-effectiveness of providing epinephrine auto-injectors to all patients receiving subcutaneous allergen
immunotherapy with aeroallergens or venoms
Anaphylaxis education
Studies of methods to increase anaphylaxis awareness among patients, caregivers, and the public
Evaluation of educational programs for all physicians, including emergency medicine and primary care physicians
Evaluation of educational programs for other healthcare personnel, including nurses and paramedics
Evaluation of educational programs for patients at risk and caregivers
Studies of the unique needs of adolescents at risk for anaphylaxis recurrence in community settings and how best to communicate effectively with them
Evaluation of educational programs for the public
Studies of resistance to change and how to facilitate change
Other
Studies on anaphylaxis guidelines implementation
Studies on development of anaphylaxis pathways
1Basic, clinical and applied sciences.
2This Table extends and amplifies the agendas for anaphylaxis research published independently by WAO and by EAACI.
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treatment and prevention of anaphylaxis recurrences and,
further, documents unmet needs in these areas. It recom-
mends increasing the awareness of anaphylaxis, continuing
to strengthen the evidence supporting recommendations
for management and prevention, and improving dissemin-
ation and implementation of anaphylaxis guidelines. It pro-
poses a comprehensive international anaphylaxis research
agenda and calls for facilitation of increased collaborations
among investigators in high-, mid- and low-resource coun-
tries. ICON: Anaphylaxis is a unique resource for physicians,
other healthcare professionals, academics, policy-makers,
patients, caregivers, and the public worldwide.
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